CEF Control Peptides
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Online Inquiry
| CAT# |
Product Name |
M.W |
Molecular Formula |
Inquiry |
| C14002 |
CEF2, Influenza Virus PA (46-54) |
1206.4 |
|
Inquiry
|
| C14003 |
CEF3, Influenza Virus M1 (13-21) |
911.1 |
|
Inquiry
|
| C14004 |
CEF4, Influenza Virus NP (342-351) |
1148.4 |
|
Inquiry
|
| C14005 |
CEF5, Influenza Virus NP (91-99) |
1019.2 |
|
Inquiry
|
| C14006 |
CEF6, Influenza Virus NP |
1051.3 |
|
Inquiry
|
| C14007 |
CEF7, Influenza Virus NP (380-388) |
1193.4 |
|
Inquiry
|
| C14009 |
CEF9, Influenza VirusM1 128-135 |
857.1 |
|
Inquiry
|
| C14010 |
CEF10, Epstein-Barr Virus LMP2 (426-434) |
906.2 |
|
Inquiry
|
| C14011 |
CEF11, Epstein-Barr Virus BMLF1 (280-288) |
920.2 |
|
Inquiry
|
| C14012 |
CEF12, Epstein-Barr Virus latent NA3B (399-408), AVF |
1136.3 |
|
Inquiry
|
| C14014 |
CEF15, Epstein-Barr Virus Lytic Cycle Protein BZLF-1(190-197) |
1003.3 |
|
Inquiry
|
| C14015 |
CEF16, Epstein-Barr Virus latent NA-3A (337-347) |
1052.3 |
|
Inquiry
|
| C14016 |
CEF17, Epstein-Barr Virus latent NA-3A (158-166) |
1143.4 |
|
Inquiry
|
| C14017 |
CEF18, Epstein-Barr Virus latent NA-3C (258-266) |
1190.4 |
|
Inquiry
|
| C14020 |
CEF21, Cytomegalovirus, CMV pp65 (417-426) |
946.1 |
|
Inquiry
|
| C14021 |
CEF22, Cytomegalovirus, CMV pp65 (378-389) |
1339.4 |
|
Inquiry
|
| C14022 |
CEF23, Cytomegalovirus, CMV pp65 (123-131) |
1079.2 |
|
Inquiry
|
| C14023 |
CEF24, Influenza Virus PB1 Peptide (591-599) |
921 |
|
Inquiry
|
| C14024 |
CEF25, Influenza Virus NP (44-52) |
1071.2 |
|
Inquiry
|
| C14025 |
CEF26, Influenza Virus NP (265-274) |
980.2 |
|
Inquiry
|
The length of CEF (Cytomegalovirus, Epstein-Barr Virus, Influenza Virus) control peptide is 8 to 12 amino acids, and its sequence is derived from human cytomegalovirus, EB virus and influenza virus 1. These peptides are used to stimulate CD8+T cells to release IFN- γ. In the detection of many kinds of cytokines such as ELISPOT, they have important application value as positive control peptides. CEF peptides were first screened in 2002 based on their ability to recognize CD8+T cells. It comes from the antigenic epitope of the virus, so it has the antigenic property.
Structure of CEF peptide
CEF peptide is composed of 8 to 11 amino acids, and the sequence is as follows: GILGFVFTL (influenza A, HLA-A2), FMYSDFHFI (influenza A, HLA-A2), CLGGLLTMV (EBV, HLA-A2), GLCTLVAML (EBV, HLA-A2), NLVPMVATV (HCMV, HLA-A2).
Function
CEF peptide can stimulate CD8+T cells to produce specific interferon-γ, which can be used as a positive control for the detection of γ-ELISA and F-Spot in human peripheral blood mononuclear cells (PBMCs). CEF control peptides are used as positive controls in ELISPOT tests to study specific immune responses to a variety of diseases, including infection, cancer, allergies and autoimmune diseases. In this case, the CEF peptide ensures that the cells in the study are active and visible. ELISPOT is also useful in developing vaccines, especially in HIV vaccines, where CEF peptides are also used as control.
References
- Xu, Y., Li, H., Gao, R. L., Adeyemo, O., Itkin, M., & Kaplan, D. E. (2011). Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. Clinical Immunology, 139(3), 302-313.
- Pohlmeyer, C. W., Laskey, S. B., Beck, S. E., Xu, D. C., Capoferri, A. A., Garliss, C. C., ... & Leffell, M. S. (2018). Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses. PloS one, 13(2), e0192098.
